Duloxetine hydrochloride

Phase 3UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Posttraumatic Stress Disorders

Conditions

Posttraumatic Stress Disorders

Trial Timeline

Dec 1, 2005 → Jun 1, 2008

NCT ID

NCT00583193

About Duloxetine hydrochloride

Duloxetine hydrochloride is a phase 3 stage product being developed by Eli Lilly for Posttraumatic Stress Disorders. The current trial status is unknown. This product is registered under clinical trial identifier NCT00583193. Target conditions include Posttraumatic Stress Disorders.

What happened to similar drugs?

3 of 3 similar drugs in Posttraumatic Stress Disorders were approved

Approved (3) Terminated (1) Active (0)

✅Placebo + sertralineJohnson & JohnsonApproved

✅Adjunctive asenapineMerckApproved

✅ZiprasidonePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00071708	Pre-clinical	Completed	—	—	Major Depressive Disorder
NCT00960986	Approved	Completed	Aug 1, 2009	Apr 1, 2011	Major Depressive Disorder (MDD)
NCT00437125	Approved	Completed	Mar 1, 2007	Jul 1, 2009	Major Depressive Disorder
NCT00266643	Approved	Completed	Dec 1, 2005	Apr 1, 2007	Diabetic Neuropathy, Painful
NCT00583193	Phase 3	UNKNOWN	Dec 1, 2005	Jun 1, 2008	Posttraumatic Stress Disorders
NCT00191594	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Major Depressive Disorder
NCT00191061	Approved	Completed	Oct 1, 2004	Jan 1, 2006	Depressive Disorder
NCT00479726	Approved	Completed	Aug 1, 2004	Jan 1, 2005	Major Depressive Disorder
NCT00036309	Phase 3	Completed	May 1, 2002	Jul 1, 2003	Depressive Disorder
NCT00036335	Phase 3	Completed	Mar 1, 2002	Jan 1, 2003	Depression

Competing Products

8 competing products in Posttraumatic Stress Disorders

See all competitors

Product	Company	Stage	Hype Score
Nepicastat + Placebo	Johnson & Johnson	Phase 2	35
Placebo + sertraline	Johnson & Johnson	Approved	35
Adjunctive asenapine	Merck	Approved	43
sertraline (Zoloft)	Pfizer	Pre-clinical	26
Ziprasidone	Pfizer	Approved	43
Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg	Brain Biotech	Phase 2	17
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis	Tilray	Phase 2	29
Riluzole	Brain Biotech	Phase 1	19